PANTOPRAZOLE AND RANITIDINE IN THE TREATMENT OF ACUTE DUODENAL-ULCER - A MULTICENTER STUDY

被引：15

作者：

SCHEPP, W

CLASSEN, M

机构：

[1] Dept. of Medicine II, Technical University of Munich, Munich

来源：

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY | 1995年 / 30卷 / 06期

关键词：

DUODENAL ULCER HEALING; PANTOPRAZOLE; RANITIDINE; SUBSTITUTED BENZIMIDAZOLES; SYMPTOM RELIEF;

D O I：

10.3109/00365529509089781

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Background: Pantoprazole is a new substituted benzimidazole that inhibits the parietal cell H+,K+-adenosine triphosphatase. Methods: Pantoprazole (40 mg) was compared with ranitidine (300 mg) in the treatment of acute duodenal ulcer. Two hundred and sixty-six patients with endoscopically diagnosed duodenal ulcers entered this multicentre, double-blind study. The primary efficacy variable was complete ulcer healing at 2 weeks; treatment then continued for a further 2 weeks if ulcers were unhealed. Results: After 2 weeks 112 of 164 (68%) patients in the pantoprazole group had healed ulcers, compared with 36 of 81 (44%) taking ranitidine (p < 0.001). After 4 weeks the cumulative healing rates were 96% and 85% (p < 0.01). Improvement in ulcer pain was also significantly better with pantoprazole than with ranitidine (81% versus 62% with no pain at 2 weeks, p < 0.01). Conclusions: Pantoprazole is clinically superior to ranitidine in the treatment of acute duodenal ulcer, in terms of both healing and symptom relief.

引用

页码：511 / 514

页数：4

共 20 条

[1]

Simon W.A., Keeling D.J., Laing S.M., Fallowfield C., Taylor A.G., BY1023/SK&F96022: biochemistry of a novel (H++ K+)-ATPase inhibitor, Biochem Pharmacol, 39, pp. 1799-1806, (1990)

[2]

Shin J.M., Besancon M., Simon A., Sachs G., The site of action of pantoprazole in the gastric H+/K+-ATPase, Biochim Biophys Acta, 1148, pp. 223-233, (1993)

[3]

Simon B., Muller P., Marinis E., Luhmann R., Huber R., Hartmann M., Et al., Effect of repeated oral administration of BY1023/SK&F96022—a new substituted benzimidazole derivative-on pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man, Aliment Pharmacol Ther, 4, pp. 373-379, (1990)

[4]

Simon B., Muller P., Hartmann M., Bliesath H., Luhmann R., Huber R., Et al., Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+K+-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers, Z Gastroenterol, 28, pp. 443-447, (1990)

[5]

Simon W.A., Budingen C., Fahr S., Kinder B., Koske M., The H+K+-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole, Biochem Pharmacol, 42, pp. 347-355, (1991)

[6]

Muller F.O., Middle M.V., Duursema L., Hundt H.K.L., Swart K.J., Schall R., Et al., Pantoprazole does not affect the pharmacodynamics and pharmacokinetics of warfarin in healthy males, Klin Pharmakol Aktuell, 2, (1993)

[7]

Schulz H.-U., Hartmann M., Steinijans V.W., Huber R., Luhrmann B., Bliesath H., Et al., Lack of influence of pantoprazole on the disposition kinetics of theophylline in man, Int J Clin Pharmacol Ther Toxicol, 29, pp. 369-375, (1991)

[8]

Gugler R., Hartmann M., Rudi J., Bliesath H., Brod I., Klotz V., Et al., Lack of interaction of pantoprazole and diazepam in man, Gastroenterology, 102, (1992)

[9]

Muller F.O., Bliesath H., Middle M.V., Hundt H.K.L., Hartmann M., Schall R., Et al., Pantoprazole does not influence the pharmacokinetics of phenytoin in man, Klin Pharmakol Aktuell, 2, (1993)

[10]

Middle M.V., Muller F.O., Mogilnicka E.M., Hundt H.K.L., Beneke P.C., Schall R., Et al., Pantoprazole does not influence ovulation suppression by a low-dose hormonal contraceptive, Klin Pharmakol Aktuell, 2, (1993)

← 1 2 →